View Older Stories View More Recent Stories
-
Novo Nordisk (NVO) PT Lowered to $159.50 at BofA Securities
-
Buy any potential weakness in this big pharma stock: JPMorgan
-
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Berenberg Reiterates Hold Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Novo Nordisk (NVO) call put ratio 1 call to 1.3 puts into Novo CEO Lars Jørgensen will testify at HELP hearing
-
BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO)
-
Novo Nordisk (NVO) call put ratio 1.7 calls to 1 put amid share price down 5.9%
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update
-
Monlunabant early obesity data not a key driver for Novo Nordisk (NVO) - BMO
-
Novo Nordisk shares fall after Monlunabant phase 2a trial results; Viking jumps
-
Corbus Pharma (CRBP) Quickly Falls 52%
-
Corbus Pharma (CRBP) sink over 55% on Novo Nordisk (NVO) data
-
Novo Nordisk (NVO) Declines 2.5% After Headline Results from Phase 2a Clinical trial with Monlunabant
-
Novo Nordisk (NVO): Monlunabant phase 2a trial in obesity successfully completed
-
Novo Nordisk (NVO): Wegovy recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
-
Novo Nordisk (NVO) option IV flat on low option volume
-
Novo Nordisk (NVO) Shares Gain 4%, See Volume Buying Pressure
-
Cantor Fitzgerald on Novo Nordisk (NVO): 'These data compare favorably to other orals in development'
-
Novo Nordisk (NVO) ADRs Continue Gains, Up ~3.5% Now
-
Roche Says Obesity Pill’s Side Effects Blunted by Gradual Dosing - Bloomberg
-
BMO Capital on Novo Nordisk (NVO): 'given that Amycretin is a peptide we would like to hear more from Novo on manufacturing, a potential point of differentiation for the small molecule assets'
-
Novo Nordisk (NVO) gains after oral amycretin presentation
-
Piper Sandler answers: who has the best obesity drug of all?
-
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,050 at JPMorgan
-
Novo Nordisk (NVO) call put ratio 1 call to 3.6 puts after Eli Lilly & Co. (LLY) launches single-dose vials of Zepbound
-
Lilly’s Zepbound cuts risk of diabetes by 94% in obese patients, shares gain
-
Deutsche Bank upgrades Eli Lilly stock to Buy, sees 15% upside potential
-
Novo Nordisk (NVO) options active on 39K contracts compared to 90-day average of 18K contracts
-
Novo Nordisk (NVO) PT Lowered to $160 at BMO Capital
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises
-
Novo Nordisk (NVO) Reports Q2 EPS of DKK10.17; raises outlook
-
Novo Nordisk (NVO) call put ratio 1 call to 1.8 puts into quarter results and outlook
-
Novo Nordisk (NVO) call put ratio 2.8 calls to 1 into quarter results
-
Citi Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Eli Lilly stock gains on new weight-loss drug study results, Novo Nordisk down
-
Roche to accelerate weight loss drugs development after positive trials - report
-
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
-
Early GLP-1 winners Lilly, Novo fall on cautious updates from rival Roche
-
UBS: GLP-1 obesity market to reach $90bn by 2029
-
Shares of this mega-cap pharma stock could outperform soon: Goldman Sachs
-
Eli Lilly shares rise as weight-loss drug receives China approval
-
Novo Nordisk (NVO) 30-day option implied volatility flat
-
Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall
-
Eli Lilly, Novo Nordisk fall as Roche's rival weight loss drug shows promise
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put as share price down 4.2%
-
Berenberg lifts its global obesity market sales forecasts to $150B by 2035
-
Novo Nordisk (NVO), Others Decline After Pfizer (PFE) Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
-
Midday movers: Nvidia, Eli Lilly rise; BP, Novo Nordisk fall
-
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
-
Novo Nordisk stock slips as Eli Lilly’s obesity drug results in faster weight loss
